Daiichi Sankyo Company (4568) Panoramica del titolo
Daiichi Sankyo Company, Limited produce e vende prodotti farmaceutici in Giappone, Nord America, Europa e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 1/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 4/6 |
4568 Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Daiichi Sankyo Company, Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | JP¥2,791.00 |
| Massimo di 52 settimane | JP¥4,178.00 |
| Minimo di 52 settimane | JP¥2,390.00 |
| Beta | -0.16 |
| Variazione di 1 mese | 9.82% |
| Variazione a 3 mesi | -6.97% |
| Variazione di 1 anno | -22.43% |
| Variazione a 3 anni | -30.86% |
| Variazione a 5 anni | 25.41% |
| Variazione dall'IPO | 261.68% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 14
4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Daiichi Sankyo Company, cutting the implied price target from ¥6,000 to ¥5,500 as they reassess expectations for revenue growth, profit margins, and the appropriate future P/E multiple. What's in the News AstraZeneca and Daiichi Sankyo secured European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
Aggiornamento narrativa • Jun 30
4568: Broad Oncology Approvals Will Support A Balanced Future Market Rating
Analysts have reduced their Daiichi Sankyo Company price target from ¥2,846.48 to ¥2,750.00, citing updated assumptions that combine slightly higher expected revenue growth with a lower profit margin outlook and a higher future P/E multiple. What's in the News for Daiichi Sankyo Company AstraZeneca and Daiichi Sankyo received European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.Recent updates
Aggiornamento narrativa • Jul 14
4568: Tumor Agnostic Oncology Approvals In Europe Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Daiichi Sankyo Company, cutting the implied price target from ¥6,000 to ¥5,500 as they reassess expectations for revenue growth, profit margins, and the appropriate future P/E multiple. What's in the News AstraZeneca and Daiichi Sankyo secured European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.Aggiornamento narrativa • Jun 30
4568: Broad Oncology Approvals Will Support A Balanced Future Market Rating
Analysts have reduced their Daiichi Sankyo Company price target from ¥2,846.48 to ¥2,750.00, citing updated assumptions that combine slightly higher expected revenue growth with a lower profit margin outlook and a higher future P/E multiple. What's in the News for Daiichi Sankyo Company AstraZeneca and Daiichi Sankyo received European Commission approval for Enhertu as a monotherapy for previously treated HER2 positive solid tumors.
Aggiornamento narrativa • Jun 16
4568: Oncology Biomarker Advances And Pipeline Approvals Will Drive Future Upside
Analysts have reduced their fair value estimate for Daiichi Sankyo Company from ¥4,736.88 to ¥4,234.71, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News Leica Biosystems expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and AI powered image analysis algorithm for the TROP2 Normalized Membrane Ratio biomarker in non small cell lung cancer, building on AstraZeneca’s computational pathology algorithm and Leica’s digital pathology platform for research use only.Aggiornamento narrativa • Jun 01
4568: Oncology Pipeline Progress And Measured Outlook Will Support Future Market Rating
Analysts have trimmed their price target for Daiichi Sankyo Company from about ¥3,065 to around ¥2,846. This reflects updated assumptions for slightly lower revenue growth, a reduced profit margin, a modestly higher discount rate, and a small adjustment to future P/E expectations.Articolo di analisi • May 13
Daiichi Sankyo Company, Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
It's been a good week for Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders, because the company has just...Aggiornamento narrativa • May 11
4568: Oncology Regulatory Progress In Lung And Breast Cancer Will Drive Upside Potential
Analysts have kept Daiichi Sankyo Company's price target steady at ¥6,000, with small adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions shaping this unchanged view. What's in the News U.S. FDA accepted and granted Priority Review for the Biologics License Application for ifinatamab deruxtecan (I DXd) in extensive stage small cell lung cancer, with an FDA action date set for October 10, 2026.Aggiornamento narrativa • Apr 23
4568: Broad Oncology Pipeline And Buyback Progress Will Support A Higher Future Market Rating
Analysts have reduced their price target on Daiichi Sankyo Company from about ¥3,623 to roughly ¥3,065, citing updated assumptions that pair lower expected revenue growth with a slightly higher profit margin outlook and a more restrained future P/E of around 20x. What's in the News The share buyback program was completed, with 31,457,200 shares repurchased for ¥91,846.79 million, representing 1.7% of shares, under the authorization announced on April 25, 2025 (Key Developments).Aggiornamento narrativa • Apr 08
4568: Oncology Approvals And Priority Reviews Will Drive Future Upside Potential
Analysts have kept their ¥6,000 price target for Daiichi Sankyo unchanged, citing slightly adjusted views on revenue growth, profit margins, and future P/E assumptions as they refine their outlook on the company. What's in the News ENHERTU (trastuzumab deruxtecan) has been approved in Japan for HER2 positive advanced or recurrent solid cancers that are refractory or intolerant to standard treatments, supported by multiple phase 2 trials and accompanied by an interstitial lung disease warning in the prescribing information (Product related announcements).Aggiornamento narrativa • Mar 25
4568: Oncology Pipeline Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target on Daiichi Sankyo Company to ¥4,736.88 from ¥4,949.38, citing slightly lower assumed profit margins and a more conservative future P/E multiple, while keeping core growth assumptions broadly unchanged. What's in the News Daiichi Sankyo and AstraZeneca’s ENHERTU and DATROWAY oncology programs continue to move through global regulators, with multiple supplemental applications and Type II variations under review in the U.S., EU, Japan and China across breast, lung, gastric and other HER2 positive or TROP2 targeted cancer indications (regulatory filings).Aggiornamento narrativa • Mar 11
4568: Priority Oncology Filings And Reviews Will Drive Future Upside Potential
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥6,300 to ¥6,000, reflecting slightly lower modeled revenue growth, a modest adjustment to profit margins, and a small uptick in the discount rate and future P/E assumptions in their updated forecasts. What's in the News The U.S. FDA accepted and granted Priority Review to a supplemental Biologics License Application for ENHERTU for certain HER2 positive early breast cancer patients with residual invasive disease after neoadjuvant therapy, with a target decision date of July 7, 2026, under Project Orbis (Key Developments).Aggiornamento narrativa • Feb 25
4568: Future Breast Cancer Franchise Progress Will Drive Further Upside For Shares
Analysts have trimmed their price target for Daiichi Sankyo Company from ¥5,546 to ¥4,949, reflecting slightly lower forecasts for revenue growth, profit margins, and future P/E multiples. What's in the News The Board of Directors of IHH Healthcare Berhad reported that NTK has filed a petition with the Tokyo District Court to amend its claims against Daiichi Sankyo, seeking to adjust an existing injunctive request related to alleged obstruction of securities transactions and corporate actions involving Fortis and Malar, while keeping its previously stated monetary and reputational reliefs unchanged (Lawsuits & Legal Issues).Aggiornamento narrativa • Feb 10
4568: Broad Oncology Pipeline Progress Will Support A Higher Future Market Rating
Analysts have lowered their price target on Daiichi Sankyo Company from ¥4,500 to about ¥3,623, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News ENHERTU received multiple regulatory milestones, including approvals in China for HER2 positive metastatic gastric cancer and for HR positive, HER2 low or ultralow metastatic breast cancer, plus U.S. Breakthrough Therapy Designation in HER2 positive early breast cancer with high recurrence risk (company announcements).Articolo di analisi • Feb 08
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend of ¥39.00 per share on the 24th...Articolo di analisi • Feb 06
There May Be Underlying Issues With The Quality Of Daiichi Sankyo Company's (TSE:4568) Earnings
Daiichi Sankyo Company, Limited's ( TSE:4568 ) robust earnings report didn't manage to move the market for its stock...Articolo di analisi • Feb 02
Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) shareholders are probably feeling a little disappointed, since its shares...Aggiornamento narrativa • Jan 26
4568: Oncology Approvals And Trials Will Drive Future Upside Potential
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300. This reflects only small model adjustments to revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the shares.Articolo di analisi • Jan 23
Daiichi Sankyo Company (TSE:4568) Is Due To Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Aggiornamento narrativa • Jan 12
4568: Expanding Oncology Pipeline And Legal Win Will Drive Future Upside
Analysts have kept their price target for Daiichi Sankyo Company steady at ¥6,300, citing only small adjustments to revenue growth, profit margin, and future P/E expectations, which supports maintaining the prior valuation view. What's in the News ENHERTU received multiple regulatory approvals and designations across the U.S., China, Canada and Europe for various HER2 positive, HER2 low and HER2 ultralow breast cancer settings, including first line metastatic treatment and early stage high risk neoadjuvant use, backed by phase 3 data from DESTINY-Breast06, DESTINY-Breast09 and DESTINY-Breast11 (Key Developments).Articolo di analisi • Jan 09
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) will pay a dividend of ¥39.00 on the 24th of June. The payment will take...Aggiornamento narrativa • Dec 27
4568: Oncology Pipeline Progress And IP Resolution Will Drive Future Upside
Analysts have nudged their price target for Daiichi Sankyo Company to ¥6,300, reflecting slightly stronger expectations for revenue growth to about 24.0 percent and a marginally higher profit margin near 21.0 percent, while maintaining a broadly similar outlook for valuation multiples. What's in the News ENHERTU received U.S. Breakthrough Therapy Designation for high risk HER2 positive early breast cancer with residual disease after neoadjuvant treatment, supported by positive phase 3 DESTINY Breast05 data and publication in The New England Journal of Medicine (Key Developments).Articolo di analisi • Dec 25
Daiichi Sankyo Company (TSE:4568) Will Pay A Dividend Of ¥39.00
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will pay a dividend on the 24th of...Aggiornamento narrativa • Dec 13
4568: Expanding Oncology Pipeline And Legal Clarity Will Drive Future Upside
Analysts have trimmed their price target on Daiichi Sankyo Company from ¥6,800 to ¥6,300. This reflects updated assumptions that pair slightly higher forecast revenue growth and profit margins with a more conservative valuation multiple and discount rate.Articolo di analisi • Dec 11
Daiichi Sankyo Company's (TSE:4568) Dividend Will Be ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) investors are due to receive a payment of ¥39.00 per share on 24th of...Aggiornamento narrativa • Nov 25
4568: Future Oncology Pipeline Success Will Drive Further Upside For Shares
Analysts have raised their price target for Daiichi Sankyo Company from ¥5,517.06 to ¥5,546.47, citing slightly higher revenue growth expectations. This increase offsets a modest rise in the discount rate and a marginal dip in projected profit margins.Articolo di analisi • Nov 04
Earnings Beat: Here's What Daiichi Sankyo Company, Limited (TSE:4568) Analysts Are Forecasting For This Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) defied analyst predictions to release its half-yearly results, which were...Aggiornamento narrativa • Oct 22
Analysts Lower Daiichi Sankyo Price Target as New Cancer Data Drives Valuation Tweaks
Narrative Update on Daiichi Sankyo Company: Analyst Price Target Adjustment Analysts have slightly reduced their fair value estimate for Daiichi Sankyo Company from ¥5,528.82 to ¥5,517.06. This adjustment reflects moderately revised assumptions around revenue growth and future earnings expectations.Aggiornamento narrativa • Oct 08
Global Aging And ADC Pipelines Will Expand Oncology Markets
Analysts have slightly raised their price target for Daiichi Sankyo Company from ¥5,459 to ¥5,529, attributing the adjustment to improved profit margin expectations. This change comes even as revenue growth projections were moderated.Articolo di analisi • Sep 21
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
The board of Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be paying its dividend of ¥39.00...Articolo di analisi • Sep 05
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Aggiornamento narrativa • Sep 04
Global Aging And ADC Pipelines Will Expand Oncology Markets
With Daiichi Sankyo's net profit margin and future P/E multiples both effectively unchanged, analysts have maintained their consensus price target at ¥5459. What's in the News DATROWAY (datopotamab deruxtecan) approved in China for HR positive, HER2 negative breast cancer after prior endocrine and chemotherapy, jointly developed with AstraZeneca.Articolo di analisi • Aug 22
Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited ( TSE:4568 ) has announced that it will be increasing its dividend from last year's...Articolo di analisi • Aug 07
Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year
Daiichi Sankyo Company, Limited ( TSE:4568 ) will increase its dividend from last year's comparable payment on the 10th...Articolo di analisi • Aug 03
Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Daiichi Sankyo Company, Limited ( TSE:4568 ) investors will be delighted, with the company turning in some strong...Articolo di analisi • Jul 24
Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00
Daiichi Sankyo Company, Limited's ( TSE:4568 ) dividend will be increasing from last year's payment of the same period...Rendimenti per gli azionisti
| 4568 | JP Pharmaceuticals | JP Mercato | |
|---|---|---|---|
| 7D | 2.2% | 0.3% | -3.5% |
| 1Y | -22.4% | 14.4% | 37.4% |
Ritorno vs Industria: 4568 ha avuto una performance inferiore rispetto al JP Pharmaceuticals che ha registrato un rendimento 14.4 % nell'ultimo anno.
Rendimento vs Mercato: 4568 ha avuto una performance inferiore al mercato JP che ha registrato un rendimento 37.4 % nell'ultimo anno.
Volatilità dei prezzi
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.1% |
Prezzo delle azioni stabile: 4568 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato JP.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di 4568 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1899 | 20,171 | Hiroyuki Okuzawa | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited produce e vende prodotti farmaceutici in Giappone, Nord America, Europa e a livello internazionale. L'azienda offre Enhertu per il trattamento di pazienti con carcinoma mammario HER2 positivo e basso, adenocarcinoma gastrico o della giunzione gastroesofagea HER2 positivo e tumori solidi HER2 positivi; Turalio, una piccola molecola orale che ha come bersaglio il recettore del fattore stimolante le colonie 1, il proto-oncogene recettore tirosin-chinasi KIT e la tirosin-chinasi 3 FMS-like che presenta una mutazione interna in tandem; Vanflyta, un inibitore di FLT3 per il trattamento di pazienti adulti con leucemia mieloide acuta; e Injectafer, un'iniezione di carbossimaltosio ferrico per il trattamento della carenza di ferro. L'azienda fornisce anche Liziana e Savaysa, inibitori diretti del fattore Xa; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar e Sevikar HCT, agenti antipertensivi; Nilemdo, un trattamento orale che riduce il colesterolo; Nustendi, un'associazione a dose fissa di acido bempedoico ed ezetimibe per ridurre il colesterolo; Efient, un agente antiaggregante piastrinico.
Daiichi Sankyo Company, Limited Riepilogo dei fondamenti
| 4568 statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | JP¥4.99t |
| Utili (TTM) | JP¥259.87b |
| Ricavi(TTM) | JP¥2.12t |
19.2x
Rapporto P/E2.4x
Rapporto P/S4568 è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| 4568 Conto economico (TTM) | |
|---|---|
| Ricavi | JP¥2.12t |
| Costo del fatturato | JP¥669.05b |
| Profitto lordo | JP¥1.45t |
| Altre spese | JP¥1.19t |
| Utili | JP¥259.87b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Jul 31, 2026
| Utile per azione (EPS) | 145.32 |
| Margine lordo | 68.49% |
| Margine di profitto netto | 12.24% |
| Rapporto debito/patrimonio netto | 18.1% |
Come si è comportato 4568 nel lungo periodo?
Vedi performance storica e confrontoDividendi
3.6%
Rendimento attuale del dividendo56%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/19 15:40 |
| Prezzo dell'azione a fine giornata | 2026/07/17 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Daiichi Sankyo Company, Limited è coperta da 28 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |